Works fast when they need it most.

A leading surfactant for treating RDS in newborns.

Infasurf delivers rapid relief through quick adsorption, ensures sustained improvement by lowering surface tension, and offers the advantage of single-dose success for enhanced lung compliance.

Why Infasurf

Rapid Relief

Sustained
Improvement

Single
Dose Success

Infasurf Products

Rapid Relief

rapid relief

Infasurf quickly lowers surface tension, which promotes rapid respiratory recovery 1,5

  • Infasurf’s SP-B content (0.74%), as a percentage of total phospholipids, helps reduce surface tension.7
  • Quickly Lowering Surface Tension1,5:
    • Helps prevent alveoli collapse
    • Increases ability to achieve equal distribution in the lung
    • Promotes rapid respiratory recovery by increasing lung compliance.
  • Infasurf demonstrates surface tension lowering activity similar to native lung surfactant1

Disclaimer: Preclinical and biologic testing do not predict clinical effects. While clinical studies have demonstrated that SP-B is an essential element, they have not determined the minimum SP-B to phospholipid ratio required for optimal surfactant efficacy.

Sustained duration of action

sustained

Infasurf demonstrates a higher rate of FiO2 improvement compared to Survanta2

  • Infasurf demonstrates a 38% higher rate of FiO2 reduction compared to Survanta in the first hour2
  • Infasurf demonstrates a superior rapid onset of action and duration of action compared to Survanta2
  • Infasurf significantly lowers FiO2 in the first hour, and throughout the next 24 hours.2
FiO2 improvement compared to Survanta

Redrawn from Bloom BT, et al., 1997

Disclaimer: Improvements in FiO2 requirements may not necessarily reduce dosing or predict long term outcomes.
Additional doses of Infasurf may be required.

Single Dose Success

Infasurf demonstrates high rates of single-dose success in two independent studies

Zayek MM, et al. JPPT. 2018;23(2):146-151.

A retrospective study comparing the pharmacy costs of Infasurf and Curosurf at the University of South Alabama Children’s and Women’s Hospital from 2010-2016. Calfactant was administered to 762 patients over 50 months, an average of 15.2 per month; poractant alfa was administered to 432 patients over 22 months, an average of 19.6 per month.

Graph redrawn from Jeon GW, et al. Yonsei Med J. 2015;56(2):433-439.
A retrospective study comparing the efficacy of Infasurf, surfactant-TA and Curosurf. A total of 332 preterm infants at 24‒31 weeks’ gestation with RDS were enrolled and allocated to three groups; Group 1 (n=146, surfactant-TA), Group 2 (n=96, calfactant), and Group 3 (n=90, poractant alfa).

There are no prospective, randomized clinical trials comparing Infasurf and Curosurf with respect to safety or efficacy.
*Proportion of single dose success, Infasurf v. Curosurf
Please see Important Safety Information. Refer to list of Re-Dose Rate Publications.

References:

  1. Notter RH, Wang Z, Egan EA, et.al. Component-specific surface and physiological activity in bovine-derived lung surfactants. Chem Phys Lipids. 2002;114:21-34.
  2. Bloom BT, Kattwinkel J, Hall RT, et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of Respiratory Distress Syndrome. Pediatrics. 1997;100:31-38. 23.
  3. Zayek MM, Eyal FG, Smith RC. Comparison of the pharmacoeconomics of calfactant and poractant alfa in surfactant replacement therapy. JPPT. 2018;23(2):146-151.
  4. Jeon GW, Oh M, Sin JB. Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with Respiratory Distress Syndrome: A retrospective study. Yonsei Med J. 2015;56(2):433-439.
  5. Seeger W, Gruba C, Gunther A, et al. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J. 1993;6:971-977.